There are calls for a national screening programme for prostate cancer: what is the evidence to justify such a national screening programme?

Abstract

Introduction

Prostate cancer is the commonest cancer in men and a major health issue worldwide. Screening for early disease has been available for many years, but there is still no national screening programme established in the United Kingdom.

Objective

To assess the latest evidence regarding prostate cancer screening and whether it meets the necessary requirements to be established as a national programme for all men.

Methods

Electronic databases and library catalogues were searched electronically and manual retrieval was performed. Only primary research results were used for the analysis.

Results

In recent years, several important randomised controlled trials have produced varied outcomes. In Europe the largest study thus far concluded that screening reduced prostate cancer mortality by 20%. On the contrary, a large American trial found no reduction in mortality after 7–10 years follow-up. Most studies comment on the adverse effects of screening – principally those of overdiagnosis and subsequent overtreatment.

Discussion

Further information about the natural history of prostate cancer and accuracy of screening is needed before a screening programme can be truly justified. In the interim, doctors and patients should discuss the risks, benefits and sequelae of taking part in voluntary screening for prostate cancer.

Keywords

Prostate cancer prostate-specific antigen screening systematic review

Get full access to this article

View all access options for this article.

References

Parkin

Bray

Ferlay

. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.

SIGN. SIGN 50: A guideline developer's handbook - Annex C: Methodology Checklist 2: Randomised controlled trials [Internet]. Retrieved from www.sign.ac.uk/guidelines/fulltext/50/checklist2.html (2004, accessed 26 November 2009).

Wilson J and Jungner G. Principles and practice of screening for disease. Public Health Paper Number 34. Geneva: WHO, 1968.

Boyle P and Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005; 16: 481–488, Retrieved from www.ncbi.nlm.nih.gov/pubmed/15718248.

Selley

Donovan

Faulkner

. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997; 1: i, 1–96.

American Cancer Society. ACS: Expectant management (watchful waiting) and active surveillance [Internet]. Retrieved from www.cancer.org/docroot/CRI/content/CRI_2_4_4X_Expectant_Therapy_Watching_and_Waiting_36.asp (2009, accessed 14 January 2010).

Barry

. Screening for prostate cancer – The controversy that refuses to die. N Engl J Med 2009; 360: 1351–1354.

Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park, NY). 2000; 14: 267–272, 277–278, 280 passim.

Heidenreich

Aus

Bolla

. European Association of Urology guidelines on prostate cancer. Eur Urol 2008; 53: 68–80.

10.

Mettlin

Lee

Drago

. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949–2958.

11.

Labrie

Candas

Dupont

. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83–91.

12.

Schroder

Hugosson

Roobol

. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–1328.

13.

Andriole

Crawford

Grubb

. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–1319.

14.

Ross

Berkowitz

Ekwueme

. Use of the prostate-specific antigen test among U.S. men: Findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008; 17: 636–644.

15.

Kjellman

Akre

Norming

. 15-year followup of a population based prostate cancer screening study. J Urol 2009; 181: 1615–1621.

16.

The UK NSC policy on Prostate cancer screening/PSA testing in men over the age of 50. The UK National Screening Programme. Retrieved from www.screening.nhs.uk/prostatecancer (accessed November 2011).

17.

Alibhai

SMH

Leach

Tomlinson

. 30-Day mortality and major complications after radical prostatectomy: Influence of age and comorbidity. J Natl Cancer Inst 2005; 97: 1525–1532.

18.

Kilpelainen TP, Tammela TLJ, Maattanen L, et al. False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer [Internet], www.dx.doi.org/10.1038/sj.bjc.6605512 (accessed 13 January 2010).